Novo Nordisk

News

Conceptual image of cogs turning in the human brain

Older GLP-1 drug shows glimmer of benefit in Alzheimer's

It's possible that Alzheimer's disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor agonists.

News

Innovent throws its hat further into China's GLP-1 ring

Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and E

News

Ozempic’s latest health benefit may be cutting dementia risk

Another week, and another study has emerged pointing to a way that GLP-1 receptor agonists may benefit human health.

News

Pfizer selects once-daily GLP-1 for its obesity push

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate.

News

FDA rejects Novo Nordisk’s weekly basal insulin

Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US.

News

Lilly scores against Novo Nordisk in weight loss contest

There’s no data from a head-to-head trial directly comparing Eli Lilly and Novo Nordisk’s GLP-1 agonist drugs yet, but an observational study has found that Lilly’s tirzepatide seems to be

Older GLP-1 drug shows glimmer of benefit in Alzheimer's

Innovent throws its hat further into China's GLP-1 ring

Ozempic’s latest health benefit may be cutting dementia risk

Pfizer selects once-daily GLP-1 for its obesity push

FDA rejects Novo Nordisk’s weekly basal insulin

Lilly scores against Novo Nordisk in weight loss contest

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

Novo Nordisk

Editor's Picks